| 1.125 -0.355 (-23.99%) | 06-12 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.82 |
1-year : | 2.56 |
| Resists | First : | 1.56 |
Second : | 2.2 |
| Pivot price | 1.25  |
|||
| Supports | First : | 0.54 |
Second : | 0.44 |
| MAs | MA(5) : | 1.32 |
MA(20) : | 1.09 |
| MA(100) : | 0.9 |
MA(250) : | 1.15 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 47.2 |
D(3) : | 48.7 |
| RSI | RSI(14): 50.3 |
|||
| 52-week | High : | 2.2 | Low : | 0.48 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HOTH ] has closed above bottom band by 42.4%. Bollinger Bands are 283.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.71 - 1.72 | 1.72 - 1.73 |
| Low: | 1.09 - 1.09 | 1.09 - 1.1 |
| Close: | 1.11 - 1.13 | 1.13 - 1.14 |
Rocket One, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in Hoboken, NJ.
Thu, 28 May 2026
Hoth Therapeutics’ pivot to AI in space sees stock price rocket - Fierce Biotech
Wed, 27 May 2026
Hoth Therapeutics stock surges on rebrand to Rocket One - Investing.com
Wed, 27 May 2026
Hoth Therapeutics completes name change to Rocket One - Investing.com
Tue, 26 May 2026
Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 2.8 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 797 (K) |
| Shares Short P.Month | 750 (K) |
| EPS | -0.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -100.9 % |
| Return on Equity (ttm) | -191.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -1.41 |
| PEG Ratio | 0 |
| Price to Book value | 2.81 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|